Lykos Gene Therapy Slashes Cholesterol

Interim results from a groundbreaking clinical trial indicate that a single dose of Lykos Therapeutics' experimental gene-editing drug can reduce LDL cholesterol by as much as 62%.

The treatment targets the PCSK9 gene in the liver, effectively 'switching off' the production of a protein that prevents the body from clearing 'bad' cholesterol.

Researchers believe this 'one-and-done' approach could revolutionize cardiovascular care by replacing the need for daily statins or monthly injections.

While the study is still in its early phases, the significant and sustained reduction in cholesterol levels has generated considerable excitement among cardiologists and pharmaceutical investors.